Bio Protocol is rolling out a new AI-driven research hub designed to bypass traditional grant bottlenecks and put funding power directly in the hands of a distributed community.
The project has unveiled OpenLabs, a platform that merges AI-assisted project design, collaborative tools, and on-chain governance into a single environment. The launch comes as Bio Protocol’s broader decentralized science (DeSci) ecosystem surpasses $33 million in capital raised, underscoring the scale of resources now flowing into alternative research funding models.
According to Bio Protocol, OpenLabs was officially introduced on June 19 during DeSci.Berlin 2026 at KÖNIG GALERIE, part of Berlin Blockchain Week. The team framed the platform as a “coordination and collaboration layer” where both humans and AI agents can transform early-stage scientific ideas into fully funded research programs.
Instead of juggling separate grant portals, governance dashboards, and communication tools, researchers using OpenLabs are expected to work within a unified interface. Here, they can outline concepts, refine them with AI-based workflows, recruit collaborators, and pitch proposals directly to token holders who decide which projects receive funding.
At the event, Bio Protocol positioned OpenLabs as a direct challenge to legacy research funding mechanisms, which often rely on lengthy peer-review cycles, opaque committee decisions, and institutional gatekeeping. In the OpenLabs model, community members evaluate and vote on proposals, while AI systems help structure, iterate, and stress-test research plans before they go on-chain for formal consideration.
The platform integrates the BIO token as its primary governance and utility asset. BIO holders can participate in proposal review, signal interest, and vote on which projects move forward, embedding funding decisions directly into the platform’s economic layer. This setup is intended to blur the line between project development and capital allocation: the same space where ideas are built is where they are financed.
Bio Protocol highlighted two early projects to illustrate how OpenLabs might be used in practice. The first, RheumaAI, is being developed as an AI agent specialized in rheumatology research, with a focus on analyzing complex clinical data and helping surface novel hypotheses about inflammatory and autoimmune diseases. The second, PeptAI, targets peptide discovery, aiming to accelerate the identification and optimization of therapeutic peptides through machine learning models and automated analysis pipelines.
Despite the product launch, market sentiment around the BIO token remained weak. BIO traded lower alongside the broader crypto sector, falling more than 8% over the past 24 hours. Traders continued to digest the more hawkish stance signaled by Federal Reserve Chair Kevin Warsh and the uncertainty surrounding the implementation of a proposed U.S.-Iran peace framework-macro factors that have affected digital assets across the board, not just DeSci-related tokens.
OpenLabs is presented as an extension of Bio Protocol’s longer-term DeSci roadmap rather than a standalone initiative. The team has been building a stack of tools and structures that rely on tokenized intellectual property and BioDAOs-decentralized organizations focused on specific areas of biology and biotechnology-to direct capital into research programs that might otherwise struggle to secure traditional grants.
At the core of this strategy is BIO Genesis, a fundraising mechanism that Bio Protocol says has raised more than $33 million so far. BIO Genesis channels capital into research-focused organizations operating within the ecosystem, effectively seeding specialized BioDAOs and research collectives that can then leverage platforms like OpenLabs to propose and execute specific projects.
Bio Protocol’s interest in AI-powered research agents predates OpenLabs. In August 2025, the project launched the Ignition Sale for Aubrai, a decentralized BioAgent developed in collaboration with VitaDAO and focused on longevity science. Aubrai is described by the team as an “on-chain AI co-scientist” capable of generating biological hypotheses, suggesting experimental designs, and assisting with the interpretation of lab results-capabilities that are now being generalized and embedded into OpenLabs’ broader workflow.
Supporters of decentralized science see initiatives like OpenLabs as part of a wider attempt to rebuild how research is funded and governed. Instead of centralized institutions controlling grant allocation, DeSci advocates envision transparent, blockchain-based systems where funding flows are visible on-chain, intellectual property rights can be tokenized and shared, and communities of scientists, patients, and backers collectively steer the direction of research.
However, the path forward is not without friction. Tokenized IP related to biotechnology inevitably sits at the intersection of securities law, patent regimes, and strict regulatory oversight of pharmaceuticals and medical devices. As projects move from exploratory studies to preclinical pipelines and clinical applications, compliance requirements can multiply, creating a legal landscape that most crypto-native teams are still learning to navigate.
Bio Protocol acknowledges that as research initiatives mature and get closer to commercialization, they must operate within existing regulatory frameworks. This raises practical questions: How do tokenized IP rights coexist with traditional patents? Who bears responsibility for safety and efficacy when decentralized communities co-fund and co-govern research? And how can compliance be maintained when critical decisions are made through open governance rather than inside a single corporation or academic institution?
OpenLabs also implicitly tests some of the most persistent criticisms of conventional grant systems. Traditional funding is often criticized for being slow, risk-averse, and biased toward established labs, senior researchers, and conservative projects. By contrast, a token-governed platform could, in theory, support riskier or underexplored ideas-particularly those that fail to fit neatly into current funding priorities but capture the interest of a global community.
Yet community-driven funding introduces its own set of risks. Popularity may not correlate with scientific merit, and token-based voting mechanisms can be skewed by wealth concentration, speculation, or social influence. Bio Protocol’s use of AI agents and structured workflows is partly aimed at mitigating these issues: before proposals go to a vote, they can be stress-tested, benchmarked, and refined according to standardized scientific criteria, theoretically making it easier for voters to distinguish serious research from hype.
From the researcher’s perspective, OpenLabs promises a more integrated experience. Instead of drafting lengthy grant applications tailored to different institutions, scientists can use AI tools to iteratively refine a single proposal, incorporate feedback from collaborators, and launch funding rounds within the same system. This could reduce administrative burden, speed up funding timelines, and encourage more cross-disciplinary collaboration by lowering the cost of experimentation-both scientifically and financially.
For early-career scientists and independent researchers without institutional backing, such a platform could provide an alternative route into competitive research fields. If OpenLabs succeeds in distributing capital based on transparent, on-chain processes, it may open doors for talent outside traditional elite universities and major pharma-backed labs. On the other hand, sustained participation will likely depend on how well Bio Protocol can bridge on-chain incentives with off-chain realities such as lab access, ethical review, and data governance.
The launch location-DeSci.Berlin-is itself part of this broader narrative. Previous editions of the conference, according to Bio Protocol, helped incubate initiatives like Molecule Labs, which has played a prominent role in experimenting with tokenized IP and community-governed biotech funding. By debuting OpenLabs in this context, Bio Protocol is signaling that it sees the platform not just as a product, but as a building block in a growing DeSci ecosystem.
In the longer term, Bio Protocol’s approach suggests a vision where AI agents, human researchers, and token-governed communities co-create and co-own research programs. AI systems such as Aubrai, RheumaAI, and PeptAI are positioned as collaborators, not just tools-entities that can iterate on hypotheses, model outcomes, and accelerate the design of experiments before a single pipette is picked up in the lab.
Whether this model can scale beyond pilot projects will depend on several factors: the robustness of the underlying AI systems, the quality of scientific output, regulatory tolerance for tokenized research structures, and the willingness of institutions, journals, and regulators to recognize data and discoveries originating from decentralized platforms.
For now, OpenLabs represents a tangible step toward testing these ideas in practice. By merging AI, token governance, and research collaboration in one environment, Bio Protocol is betting that the future of science funding will be more open, more programmable, and more directly shaped by the communities that stand to benefit from its outcomes-rather than by a small group of traditional grant gatekeepers.